+ All Categories
Home > Documents > Cancer Genetics Lec 3 and 4

Cancer Genetics Lec 3 and 4

Date post: 14-Apr-2018
Category:
Upload: aayudh-das
View: 216 times
Download: 0 times
Share this document with a friend

of 13

Transcript
  • 7/30/2019 Cancer Genetics Lec 3 and 4

    1/13

    Cancer genetics-Aayudh Das

    CANCER GENETIC

    Alternative Pathways to Cancer

    Deletion or inactivation of tumor su

    example, it was shown in the slide o

    and 17p, which contain the DCC (delet

    progression of colon carcinoma.

    3

    The paths that cells ta

    malignant are highly v

    type mutation of part

    ras or p53 may beotherwise histologicall

    In familial cancer cas

    frequently in the fa

    they already have.

    already 1 copy is in

    acquired. In Familial A

    2 copies are mutated

    malignant.

    Familial cancer sugg

    that probably occurre

    there may be a comb

    genetic (i.e., envi

    contributed to the dev

    family. In such instan

    single major gene is n

    individuals may still fa

    ppressor genes can give rise to either famil

    the evolution of colon cancer that deletions

    ed in colon carcinoma) and the p53 genes, res

    Page 1

    ke on their way to becoming

    riable. Within a given cancer

    icular target genes such as

    found in only a subset ofy identical tumors.

    es, the cancer occurs more

    ily than in the population

    Onset is also frequent as

    herited, 1 more has to be

    denomatous Polyposis when

    then benign tumor becomes

    sts a clustering of cancers

    by chance. In other words,

    ination of genetic and non-

    ronmental) factors that

    elopment of cancers within a

    ces, where an alteration in a

    ot likely or is not identified,

    ce elevated risks of cancer.

    ial or sporadic cancer. For

    of chromosome regions 18q

    pectively, are involved in the

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    2/13

    Cancer genetics-Aayudh Das Page 2

    The Rb gene and the p53 gene will be the subjects of further discussion. The next three slides look at the

    mechanisms by which tumor suppressor genes get mutated to give rise to familial and sporadic cancers.

    RETINOBLASTOMA PROTEIN

    The retinoblastoma protein (abbreviated pRb, RBor RB1) is a tumor suppressor protein that is dysfunctional

    in several major cancers. One function of pRb is to prevent excessive cell growth by inhibiting cell

    cycle progression until a cell is ready to divide. It is also a recruiter of several chromatin remodeling enzymessuch as methylases and acetylases.

    pRb belongs to the pocket protein family, whose members have a pocket for the functional binding of other

    proteins. Should an oncogenic protein, such as those produced by cells infected by high-risk types of human

    papillomaviruses, bind and inactivate pRb, this can lead to cancer.

    About 40% retinoblastoma cases are familial

    It inherits as incompletely penetrant dominant character

    Familial cases are bilateral, whereas the sporadic forms are unilateral

    Age-of-onset distribution of bilateral cases is consistent with a single mutation, while sporadic

    cases followed two-hit kinetics.

    In 1971Knudson proposed that all retinoblastoma involved two hits, but that in the familial cases

    one hit was inherited

    The vast majority of cancers are non-hereditary ("sporadic cancers"). Hereditary cancers (familial) are primarily

    caused by an inherited genetic defect.

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    3/13

    Cancer genetics-Aayudh Das Page 3

    Retinoblastoma arises when both copies of the RB gene

    are inactivated. In the inherited form of the disease, one

    parental chromosome carries an alteration in this

    region. Asomatic event in retinal cells that causes loss of

    the other copy of the RB gene causes a tumor. In the

    sporadic form of the disease, the parental chromosomes

    are normal, and both RBalleles are lost by (individual)somatic events.

    In 1978 Yunis and Francke showed thatretinoblastoma tumor had deletion in chromosome 13q14.

    In 1983, recessive nature of the retinoblastoma gene was hypothesized and it was suggested thatboth

    alleles of this gene would need to be inactivated for retinoblastoma to arise

    RFLP analysis of the 13q14 region showed heterozygous state in normal cells of a Rb patient but

    hemizygous ( only one allele instead of two in a diploid cell) in the tumor tissue of the sameindividual.

    This loss of heterozygosity (LOH) suggests thatRb arises through loss of both functional RB alleles

    Loss of both wild type alleles is seen both in familial and sporadic form of Rb.

    In the familial form, one germline mutation is inherited, followed by a 2nd somatic event; in the

    sporadic form both events are somatic.

    Cell-cycle dependent phosphorylation of Rb

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    4/13

    Cancer genetics-Aayudh Das Page 4

    Function of the Rb protein

    Tumour suppressors may control the cell cycle

    As well as occurring in RB itself, mutations are found in the small inhibitory proteins (most notably pi6 and

    possibly p21), and D cyclin(s). Although these proteins (most notably RB) play a role in the cycle of a

    proliferating cell, the role that is relevant for tumorigenesis is more probably their function in the quiescent (GO)

    state. In quiescent cells, RB is not phosphorylated, D cyclin levels are low or absent, and pi6, p21, and p27 ensure

    inactivity of cdk-cyclin complexes.

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    5/13

    Cancer genetics-Aayudh Das Page 5

    Chromosomal mechanisms that could lead to loss of function due to loss of

    heterozygosity (LOH)

    Detection of TSG by LOH Analysis

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    6/13

    Cancer genetics-Aayudh Das Page 6

    The p53 Functional Circuit

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    7/13

    Cancer genetics-Aayudh Das Page 7

    Tumor suppressor p53 suppresses growth or triggers apoptosis

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    8/13

    Cancer genetics-Aayudh Das Page 8

    The Mutation Spectrum of p53

    p53 is a DNA-binding protein that recognizes an

    interrupted palindromic 10 bp motif. The

    ability to bind to its specific target sequences is

    conferred by the central domain.

    p53 activates transcription at promoters that

    contain multiple copies of this motif. The

    immediate N-terminal region provides the

    transactivator domain. p53 may repress other

    genes; the mechanism is unknown.

    p53 also has the ability to bind to damaged

    DNA. The C-terminal domain recognizes single-

    stranded regions in DNA.

    p53 is a tetramer (oligomerization is a

    prerequisite for mutants to behave in a

    dominant negative manner). Oligomerization

    requires the C-terminal region.

    A (putative) signaling domain contains copies

    of the sequence PXXP, which forms a binding

    site for SH3 domains.

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    9/13

    Cancer genetics-Aayudh Das Page 9

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    10/13

    Cancer genetics-Aayudh Das Page 10

    RB-p53-CDKN2A (INK4A)-p21Network

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    11/13

    Cancer genetics-Aayudh Das Page 11

    APC and FAP

    Intracellular protein

    Truncations in APC

    Aberrant activation of Wnt pathway

    Increased cell proliferation and adenomatous lesions

    Autosomal dominantly inherited disease

    Hundreds or thousands of polyps in the colon and rectum

    Mutations in APC also found in:

    Sporadic colon cancer

    Several types of tumours

    Hepatocellular carcinoma

    Wnt signaling and cancer

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    12/13

    Cancer genetics-Aayudh Das Page 12

  • 7/30/2019 Cancer Genetics Lec 3 and 4

    13/13

    Cancer genetics-Aayudh Das Page 13


Recommended